-
Jan 26, 2023
invoX Pharma and F-star Therapeutics issue Joint Statement -
Dec 06, 2022
F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress -
Nov 07, 2022
F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research -
Aug 11, 2022
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights -
Aug 04, 2022
invoX Pharma Extends Tender Offer to Acquire F-star Therapeutics, Inc. -
Jul 20, 2022
F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody -
Jun 23, 2022
invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs -
May 10, 2022
F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update -
May 02, 2022
F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022 -
Apr 08, 2022
F-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022
Pagination
